文献速递免疫规划传染病防控与疫情报告

BECC佐剂血凝素流感疫苗增强免疫原性与保护效力

BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy.
PubMed 文献 · Vaccine · 2026-05-31

本研究在小鼠流感病毒感染模型中评估生物来源及全合成BECC脂质A佐剂联合重组血凝素(rHA)的免疫原性与保护效力。BECC佐剂化rHA可强效激活体液与细胞免疫,合成化合物BECC470s在清除病毒和维持长效免疫记忆方面表现更优,提示其作为下一代合成佐剂提升重组流感疫苗保护广度与持久性的潜力。

要点

  • BECC佐剂化rHA可同时增强体液与细胞免疫应答。
  • BECC470s在攻毒后7天内实现快速病毒清除。

核心结论

  • BECC470s是具前景的下一代合成佐剂,可提升重组流感疫苗免疫保护的广度与持久性。

研究设计与样本

  • 研究在小鼠流感病毒感染模型中评价生物来源与全合成BECC脂质A佐剂联合重组血凝素(rHA)的免疫原性与保护效力。

主要发现

  • BECC佐剂化rHA可强效激活体液与细胞免疫应答。
  • BECC配方诱导强效HA特异性抗体应答,Th1相关IgG2a亚类较基准佐剂MPL和PHAD显著增加。
  • 合成化合物BECC470s在BECC候选中表现更优,攻毒后7天内观察到快速病毒清除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Seasonal influenza viruses continue to pose a significant threat, causing substantial morbidity and mortality in the US and worldwide despite the availability of vaccines and antivirals. These challenges may be addressed by improving vaccine immunogenicity through the inclusion of adjuvants that enhance immune responses against key antigens, including influenza hemagglutinin (HA). BECC (Bacterial Enzymatic Combinatorial Chemistry) adjuvants are novel Toll-like Receptor 4 (TLR4) ligands created by modifying enzymes from lipid A synthesis pathways in Gram-negative bacteria. This study specifically evaluated the immunogenicity and protective efficacy of biologically derived and fully synthetic Bacterial Enzymatic Combinatorial Chemistry (BECC) lipid A-based adjuvants in combination with recombinant hemagglutinin (rHA) antigens in a murine model of influenza virus infection. Immunization with BECC-adjuvanted rHA elicited strong activation of both humoral and cellular immune responses. Notably, BECC formulations induced robust HA-specific antibody responses, with a marked increase in the Th1-associated IgG2a subclass as compared to the benchmark adjuvants monophosphoryl lipid A (MPL) and PHAD. Among the BECC candidates, the synthetic compound BECC470s demonstrated superior efficacy, with rapid viral clearance observed by seven days post-challenge. Additionally, BECC-adjuvanted vaccination enhanced immune recognition of linear B- and T-cell epitopes and sustained durable immune memory responses for up to eighteen months following immunization. Collectively, these findings highlight BECC470s as a promising next-generation synthetic adjuvant with substantial potential for improving the breadth and durability of immune protection afforded by recombinant influenza vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Das S, Tenaglia BM, Riley D, et al. BECC-adjuvanted hemagglutinin influenza vaccine promotes enhanced immunogenicity and protective efficacy. Vaccine. 2026. PMID: 42218860. doi:10.1016/j.vaccine.2026.128774

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。